Molecular targets in melanoma: time for ‘ethnic personalization’

References

• Ries LA, Wingo PA, Miller DS et al. The annual report to the nation on the status of cancer, 1973–1997, with a special section on colorectal cancer. Cancer88, 2398–2424 (2000).
   PubMed Web of Science ®Google Scholar
• Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol.27(36), 6199–6206 (2009).
   PubMed Web of Science ®Google Scholar
• Berwick M, Erdei E, Hay J. Melanoma epidemiology and public health. Dermatol. Clin.27, 205–214, viii (2009).
   PubMed Web of Science ®Google Scholar
• Cress RD, Holly EA. Incidence of cutaneous melanoma among non-Hispanic whites, Hispanics, Asians, and blacks: an analysis of California Cancer Registry data, 1988–93. Cancer Causes Control8(2), 246–252 (1997).
   PubMedGoogle Scholar
• Hu S, Parmet Y, Allen G et al. Disparity in melanoma: a trend analysis of melanoma incidence and stage at diagnosis among whites, Hispanics, and blacks in Florida. Arch. Dermatol.145(12), 1369–1374 (2009).
   PubMed Web of Science ®Google Scholar
• Johnson D, Yamane S, Morita S et al. Malignant melanoma in non-Caucasians: experience from Hawaii. Surg. Clin. N. Am.83, 275–282 (2003).
   Google Scholar
• Cormier JN, Xing Y, Ding M et al. Ethnic differences among patients with cutaneous melanoma. Arch. Intern. Med.166(17), 1907–1914 (2006).
   PubMedGoogle Scholar
• Curtin JA, Fridlyand J, Kageshita T et al. Distinct sets of genetic alterations in melanoma. N. Engl. J. Med.353(20), 2135–2147 (2005).
   PubMed Web of Science ®Google Scholar
• Ashman LK. The biology of stem cell factor and its receptor c-KIT. Int. J. Biochem. Cell. Biol.31, 1037–1051 (1999).
   PubMed Web of Science ®Google Scholar
• Funasaka Y, Boulton T, Cobb M et al. c-KIT-kinase induces a cascade of protein tyrosine phosphorylation in normal human melanocytes in response to mast cell growth factor and stimulates mitogen-activated protein kinase but is downregulated in melanomas. Mol. Biol. Cell3(2), 197–209 (1992).
   PubMedGoogle Scholar
• Natali PG, Nicotra MR, Sures I et al. Expression of c-KIT receptor in normal and transformed human nonlymphoid tissues. Cancer Res.52, 6139–6143 (2002).
   Google Scholar
• Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol.24(26), 4340–4346 (2006).
   PubMed Web of Science ®Google Scholar
• Smalley KS, Sondak VK, Weber JS. c-KIT signaling as the driving oncogenic event in subgroups of melanomas. Histol. Histopathol.24(5), 643–650 (2009).
   Google Scholar
• Ugurel S, Hildenbrand R, Zimpfer A et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br. J. Cancer92(8), 1398–1405 (2005).
   PubMed Web of Science ®Google Scholar
• Wyman K, Atkins MB, Prieto V et al. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer106(9), 2005–2011 (2006).
   PubMed Web of Science ®Google Scholar
• Hodi FS, Friedlander P, Corless CL et al. Major response to imatinib mesylate in KIT-mutated melanoma. J. Clin. Oncol.26(12), 2046–2051 (2008).
   PubMed Web of Science ®Google Scholar
• Lutzky J, Bauer J, Bastian BC. Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res.21(4), 492–493 (2008).
   PubMed Web of Science ®Google Scholar
• Carvajal RD, Chapman PB, Wolchok JD et al. A Phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT. J. Clin. Oncol.27(Suppl.), 15s (2009) (Abstract 9001).
   Google Scholar
• Carvajal RD, Antonescu CR, Wolchok JD et al. KIT as a therapeutic target in metastatic melanoma. JAMA305(22), 2327–2334 (2011).
   PubMed Web of Science ®Google Scholar
• Meier F, Busch S, Lasithiotakis KG et al. Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. Br. J. Dermatol.156, 1204–1213 (2007).
   PubMed Web of Science ®Google Scholar
• Ball NJ, Yohn JJ, Morelli JG et al.RAS mutations in human melanoma: a marker of malignant progression. J. Invest. Dermatol.102, 285–290 (1994).
   PubMed Web of Science ®Google Scholar
• Devitt B, Liu W, Salemi R et al. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res.24(4), 666–672 (2011).
   PubMed Web of Science ®Google Scholar
• Sweet RW, Yokoyama S, Kamata T et al. The product of RAS is a GTPase and the T24 oncogenic mutant is deficient in this activity. Nature311(5983), 273–275 (1984).
   PubMed Web of Science ®Google Scholar
• Kumar R, Angelini S, Snellman E, Hemminki K. BRAF mutations are common somatic events in melanocytic nevi. J. Invest. Dermatol.122(2), 342–348 (2004).
   PubMed Web of Science ®Google Scholar
• Flaherty K, Puzanov I, Sosman J et al. Phase I study of PLX 4032: BRAF mutation as a therapeutic target in human cancer. J. Clin. Oncol.27(Suppl.), 15 (2009).
   Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med.364(26), 2507–2516 (2011).
   PubMed Web of Science ®Google Scholar
• Eisen T, Ahmad T, Flaherty KT et al. Sorafenib in advanced melanoma: a Phase II randomized discontinuation trial analysis. Br. J. Cancer95, 581–586 (2006).
   PubMed Web of Science ®Google Scholar
• Hauschild A, Agarwala SS, Trefzer U et al. Results of a Phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J. Clin. Oncol.27, 2823–2830 (2009).
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Lee S, Schuchter LM et al. Final results of E2603: a double-blind, randomized Phase III trial comparing carboplatin/paclitaxel with or without sorafenib in metastatic melanoma. J. Clin. Oncol.28(7S), 8511 (2010).
   Google Scholar
• Ribas A, Kim KB, Schuchter LM et al. BRIM-2: an open-label, multicenter Phase II study of vemurafenib in previously treated patients with BRAF V600E mutation positive melanoma. J. Clin. Oncol.29(Suppl.), (2011) (Abstract 8509).
   Google Scholar
• Nazarian R, Shi H, Wang Q et al. Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation. Nature468, 973–977 (2010).
   PubMed Web of Science ®Google Scholar
• Johannessen CM, Boehm JS, Kim SY et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature468, 968–972 (2010).
   PubMed Web of Science ®Google Scholar
• Solit DB, Garraway LA, Pratilas CA et al.BRAF mutation predicts sensitivity to MEK inhibition. Nature439, 358–362 (2006).
   PubMed Web of Science ®Google Scholar
• Wagle N, Emery C, Berger MF et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol.29(22), 3085–3096 (2011).
   PubMed Web of Science ®Google Scholar
• Reiling JH, Sabatini DM. Stress and mTORture signaling. Oncogene25, 6373–6383 (2006).
   PubMed Web of Science ®Google Scholar
• Dai D, Martinka M, Li G. Prognostic significance of activated Akt expression in melanoma: a clinico–pathologic study of 292 cases. J. Clin. Oncol.23(7), 1473–1482 (2005).
   PubMed Web of Science ®Google Scholar
• Stahl JM, Sharma A, Cheung M et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res.64(19), 7002–7010 (2004).
   PubMed Web of Science ®Google Scholar
• Curtin JA, Stark MS, Pinkel D, Hayward NK, Bastian BC. PI3-kinase subunits are infrequent somatic targets in melanoma. J. Invest. Dermatol.126(7), 1660–1663 (2006).
   PubMed Web of Science ®Google Scholar
• Dronca RS, Perez DG, Allred J et al. N0675: NCCTG Phase II study of TMZ and RAD001 therapy for metastatic melanoma. J. Clin. Oncol.28(Suppl.), 15s (2010) (Abstract 8572).
   Google Scholar
• Hainsworth JD, Infante JR, Spigel DR et al. Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a Phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer116(17), 4122–4129 (2010).
   PubMed Web of Science ®Google Scholar
• Akslen LA, Puntervoll H, Bachmann IM et al. Mutation analysis of the EGFR–NRAS546 pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. Melanoma Res.18(1), 29–35 (2008).
   Google Scholar
• Maldonado JL, Fridlyand J, Patel H et al. Determinants of BRAF mutations in primary melanomas. J. Natl Cancer Inst.95(24), 1878–1890 (2003).
   PubMed Web of Science ®Google Scholar
• Sasaki Y, Niu C, Makino R et al.BRAF point mutations in primary melanoma show different prevalences by subtype. J. Invest. Dermatol.123(1), 177–183 (2004).
   Google Scholar
• Takata M, Goto Y, Ichii N et al. Constitutive activation of the mitogen-activated protein kinase signaling pathway in acral melanomas. J. Invest. Dermatol.125(2), 318–322 (2005).
   PubMed Web of Science ®Google Scholar
• Terada T. Low incidence of KIT gene mutations and no PDGFRA gene mutations in primary cutaneous melanoma: an immunohistochemical and molecular genetic study of Japanese cases. Int. J. Clin. Oncol.15(5), 453–456 (2010).
   Google Scholar
• Yun J, Lee J, Jang J et al. KIT amplification and gene mutations in acral/mucosal melanoma in Korea. APMIS119(6), 330–335 (2011).
   PubMed Web of Science ®Google Scholar
• Cho JH, Kim KM, Kwon M, Kim JH, Lee J. Nilotinib in patients with metastatic melanoma harboring KIT gene aberration. Invest. New Drugs doi:10.1007/s10637-011-9763-9 (2011) (Epub ahead of print).
   Google Scholar
• Chi Z, Li S, Sheng X, Si L, Cui C, Han M, Guo J. Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases. BMC Cancer11, 85 (2011).
   PubMed Web of Science ®Google Scholar
• Si L, Kong Y, Xu X et al. Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur. J. Cancer48(1), 94–100 (2012).
   PubMed Web of Science ®Google Scholar
• Ellerhorst JA, Greene VR, Ekmekcioglu S et al. Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin. Cancer Res.17(2), 229–235 (2011).
   PubMed Web of Science ®Google Scholar
• Akslen LA, Angelini S, Straume O et al.BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. J. Invest. Dermatol.125(2), 312–317 (2005).
   PubMed Web of Science ®Google Scholar
• Qi RQ, He L, Zheng S et al.BRAF exon 15 T1799A mutation is common in melanocytic nevi, but less prevalent in cutaneous malignant melanoma, in Chinese Han. J. Invest. Dermatol.131(5), 1129–1138 (2011).
   PubMed Web of Science ®Google Scholar
• Kong Y, Si L, Zhu Y et al. Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin. Cancer Res.17(7), 1684–1691 (2011).
   PubMed Web of Science ®Google Scholar
• Guo J, Si L, Kong Y et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-KIT mutation or amplification. J. Clin. Oncol.29(21), 2904–2909 (2011).
   PubMed Web of Science ®Google Scholar
• Cohen MH, Dagher R, Griebel DJ et al. US Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid. Oncologist7(5), 393–400 (2002).
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature417(6892), 949–954 (2002).
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Yasothan U, Kirkpatrick P. Vemurafenib. Nat. Rev. Drug Discov.10(11), 811–812 (2011).
   PubMed Web of Science ®Google Scholar
• Jim SY, On S, Lum CA et al. Acral lentiginous melanoma in Hawaii: characterization of the mTOR pathway in the non-Caucasian population. J. Clin. Oncol.29(Suppl.), (2011) (Abstract 8592).
   Google Scholar
• Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized Phase II trial of for previously treated patients with advanced non-small-cell lung cancer (IDEAL 1 trial). J. Clin. Oncol.21(12), 2237–2246 (2003).
   PubMed Web of Science ®Google Scholar
• Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small-cell lung cancer: a randomized trial. JAMA290(16), 2149–2158 (2003).
   PubMed Web of Science ®Google Scholar